Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Rho GTPase cross-talk with syndecan-4 regulates pro-fibrotic mechanotransduction in the heart (ROCKSOFT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-04-01
End date: 2021-03-31
Duration (months): 24.0
Total project cost (EUR): 212194.8
EU funding (EUR): 212194.8
Participants: 1
Project status: CLOSED

Cardiac fibrosis is a major cause of diastolic heart failure, a condition affecting millions of people worldwide. Treatment is currently lacking, reflecting a lack of understanding of cardiac fibroblast physiology, the main cell type responsible for extracellular matrix (ECM) production and development of fibrosis. Mechanical stress activates cardiac fibroblasts causing differentiation into myofibroblasts with excessive production of ECM. I previously showed that syndecan-4 (SDC4) is essential for myofibroblast differentiation in response to mechanical stress, although the exact mechanism was not fully elucidated. SDC4 regulates Rho GTPases and Ca2+ influx through TRPC7 channels, previously suggested to be stretch-activated. Thus, we hypothesize that SDC4-dependent Ca2+ signalling and Rho GTPase activation are crucial for translating mechanical stress into pro-fibrotic fibroblast activity. Despite having Ca2+ binding properties on the extracellular part, no studies have examined the role of SDC4 in regulating extracellular Ca2+ distribution and dynamics. Based on preliminary data, we here introduce the novel concept of extracellular Ca2+ microdomains that are created and maintained by SDC4. These microdomains are conceivably affected by changes in cell contraction and actin cytoskeleton organisation, thus promoting fibrotic remodelling of the heart in response to aberrant Rho GTPase signalling in the fibroblasts. To investigate these hypotheses in cardiac fibroblasts, I have developed a novel in vitro model that combines stiffness and stretch to induce myofibroblast differentiation, and study the process using state-of-the art CRISPR gene editing. The expertise of Prof. Cord Brakebusch in Rho GTPase function and CRISPR combined with my expertise in SDC4 mechanotransduction in cardiac fibroblasts will substantiate the success of this project, potential discovery of novel therapeutic targets and the possibility for me to create an impactful research group profile.

Keywords: mechanotransduction,cardiac fibroblasts,myofibroblasts,fibrosis,heart failure,syndecan 4,rho gtpases,mechanical stress,calcium
Control and measurement of single macromolecules in space and time (COSMOS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physical and analytical chemical sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Switzerland,United Kingdom
Call: ERC Consolidator Grant (ERC-2016-COG, 2016)
Start date: 2018-06-01
End date: 2024-05-31
Duration (months): 72.0
Total project cost (EUR): 2124965.0
EU funding (EUR): 2124965.0
Participants: 2
Project status: SIGNED

The desire to “freely suspend the constituents of matter” in order to study their behaviour can be traced back over 200 years to Lichtenberg’s diaries. From radio-frequency ion traps to optical tweezing of colloidal particles, existing methods to trap matter in free space or solution rely on the use of external fields that often strongly perturb the integrity of a macromolecule in solution. Recently, I invented the ‘electrostatic fluidic trap’, a “field-free” principle that supports stable, non-destructive confinement of single macromolecules in room temperature fluids, representing a paradigm shift in a nearly century-old field. The spatio-temporal dynamics of a single electrostatically trapped molecule reveals fundamental information on its properties, e.g., size and electrical charge. The charge of a macromolecule is in turn a strong function of its 3D conformation - the molecular basis of biological function. I now aim to develop a new platform to study 3D macromolecular structure and temporal conformation by measuring the electrical charge of a single trapped molecule in real time, using both optical microscopy and electrical detection. Beyond the conformational dynamics of a single molecule, we will also examine interactions between two or more molecules, and the detection of minute structural differences between closely related molecular isoforms. We will further develop a novel approach to electrical transport measurements on single molecules aimed at generating for the first time a catalog of ‘electrical signatures’ for biomolecules in solution. The ability to experimentally link electrical charge and molecular structure will not only open up a new physical dimension in our understanding of macromolecules, but also advance the development of ultrasensitive, high-throughput molecular sensors for biomedical detection and analytics, potentially enabling an optical or electrical “single-snapshot” read-out of the proteome or transcriptome of a single cell.

Keywords: single molecule trapping,nanoscale electrostatics,molecular electrometry
EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine. (EUCANCan)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Spain,Germany,Spain,France,Netherlands,Canada
Call: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches (H2020-SC1-2018-Single-Stage-RTD, 2018)
Start date: 2019-01-01
End date: 2023-06-30
Duration (months): 54.0
Total project cost (EUR): 6527563.75
EU funding (EUR): 5999452.75
Participants: 21
Project status: SIGNED

We propose to create the EUropean-CANadian Cancer network (EUCANCan), a federated infrastructure whose mission is to enable Personalized Medicine in Oncology by promoting the generation and sharing of harmonized genomic and phenotypic data. EUCANCan builds on work performed by members of the consortium and related projects to align and interconnect existing European and Canadian infrastructures for the analysis and management of genomic oncology data. The EUCANCan network will be composed of reference nodes in Amsterdam, Barcelona, Berlin, Heidelberg, Paris and Toronto which have established strong research and clinical programs in the field of genomic oncology. These reference nodes will work together in an interoperable fashion to provide the genomic oncology community with a uniform computing environment for the processing, harmonization and secure sharing of cancer genome and phenome data in the context of clinical research, enabling the discovery of clinically-relevant patterns of variation in the cancer genome such as biomarkers predictive of therapeutic response. The infrastructure will also provide a proving ground for federated genome analysis systems that may one day be integrated into national and regional healthcare systems. EUCANCan’s objectives are: (1) harmonise protocols for the identification and interpretation of germline and somatic variation profiles within cancer genomes; (2) generate strategies for the flow, management, storage and distribution of data within and across EUCANCan nodes; (3) define community standards for data elements, types and formats; (4) develop an open and accessible data portals for the searching and download of EUCANCan data; and (5) define an appropriate ethical and legal frame to ensure the secure sharing of protected individual genomic and phenotypic data across countries.

Keywords: genomics,standardization,data sharing,harmonization,cancer
pilot embedded Systems arcHItecturE for multi-Layer Dependable solutions (PS.HI.E.L.D.)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Norway,Spain,Italy,Italy,Greece,Portugal,Spain,Slovenia
Call:  (ARTEMIS-2009-1, 2009)
Start date: 2010-06-01
End date: 2011-11-30
Duration (months): 18.0
Total project cost (EUR): 5392810.07
EU funding (EUR): 900599.27
Participants: 17
Project status: CLOSED

-
Process Oriented Electrical Control Units for Electrical Vehicles Developed on a Multi-system Real-time Embedded Platform (POLLUX)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Embedded Computing Systems
Action type: Collaborative project
Partnership: ARTEMIS (Art-185)
Countries involved: Norway,Italy,Netherlands,Austria,Belgium,Italy,Austria,France,France,Austria,Spain,France,France,United Kingdom,United Kingdom,Czechia,Spain,Belgium,Czechia,Germany,United Kingdom,Spain,Germany,Netherlands
Call:  (ARTEMIS-2009-1, 2009)
Start date: 2010-03-01
End date: 2013-09-30
Duration (months): 43.0
Total project cost (EUR): 32939301.95
EU funding (EUR): 5500863.42
Participants: 36
Project status: CLOSED

The objective of POLLUX is to develop a distributed real time embedded systems platform for next generation electric vehicles, by using a component and programming-based design methodology. Reference designs and embedded systems architectures for high efficiency innovative mechatronics systems will be addressed with regard to requirements on composability, networking, security, robustness, diagnosis, maintenance, integrated resource management, evolvability and self-organization. Next generation EVs will begin the convergence between computer and automotive architectures: future automobiles will be mechatronic systems comprising a multitude of plug-and-play and self configurable peripherals. Peripherals will be embedded systems containing hardware, algorithms, software. The architecture will be based on distributed energy while the propulsion systems will adopt radical new control concepts. Sensing, actuation, signal processing and computing devices will be embedded in the electronic equipment, electrical motors, batteries and the mechanical parts as well. The systems used to control the chassis and the power train will form the “computing engine” that automates lower level tasks during vehicle use (driver assistance, terrain evaluation, predictive battery management) and will enable future higher level functionalities (auto pilot), by means of novel human-machine interfaces. POLLUX addresses the embedded system needs for the next generation electric vehicles by exploiting the synergy with the ENIAC E3Car project which aims to develop nanoelectronics technologies, devices, circuits, and modules for EVs in preparation for the launch of a massive European EV market by 2015-2020. The project considers both vertical integration and horizontal cooperation between OEMs, hardware/software/silicon providers to build a solid, embedded-systems European industry while establishing standard designs and distributed real-time embedded-systems platforms for EVs. Approved in its amended version (JUGA amendment n 1) on 10/05/2012
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,Spain,Spain,Germany,United Kingdom,Denmark,Austria,Netherlands,Germany,Sweden,Germany,Germany,Belgium,Denmark,Belgium,Germany,France,Germany,Netherlands,United Kingdom,Spain,Austria,United Kingdom
Call:  (IMI-JU-01-2008, 2008)
Start date: 2010-01-01
End date: 2016-12-31
Duration (months): 84.0
Total project cost (EUR): 18787108.0
EU funding (EUR): 6910018.0
Participants: 30
Project status: CLOSED

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modelling of the complex relationships existing between molecular and in vitro information and the in vivo toxicity outcomes of drugs. The proposed strategy includes a synergetic integration of innovative approaches in the following areas: Database building and management, including masking procedures for sensitive data, with the aim of facilitating the sharing of information among pharmaceutical companies. • Ontologies and text mining techniques, with the purpose of facilitating knowledge extraction from legacy preclinical reports and biomedical literature. • Chemistry and structure-based approaches for the molecular description of the compounds considered, as well as of the biological anti-targets responsible for the secondary pharmacologies. • Prediction of absorption and metabolism since these ADME properties are often critically related to toxicological events. • Computational genomics to afford the inter-species and inter-individual variabilities that complicate the interpretation of experimental and clinical outcomes. • Systems biology approaches in order to cope with the complex biological mechanisms which govern in vivo safety problems. • Sophisticated statistical analysis tools required to derive the inevitably highly-multivariate QSAR models. • Development and validation (according to the OECD principles) of QSARs, integrative models, expert systems and meta-tools. • Linkage of toxicity preclinical data with human outcomes

Keywords: etox
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,Netherlands,Germany,United Kingdom,Sweden,Denmark,Netherlands,France,France,Germany,Sweden,Austria,France,Portugal,Germany,Spain,Germany,Germany,Belgium,Denmark,Finland
Call:  (IMI-JU-01-2008, 2008)
Start date: 2010-01-01
End date: 2016-09-30
Duration (months): 81.0
Total project cost (EUR): 5982422.0
EU funding (EUR): 2374904.0
Participants: 33
Project status: CLOSED

Background: In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objectives: We present a new and unique pan-European education and training network, which solves this shortfall by developing and establishing a comprehensive modular Education and Training Programme in Safety Sciences for Medicines (SafeSciMET). This programme will fulfil the needs of pharmaceutical industry, regulatory authorities and academia. The network, consisting of top institutes for drug safety education and research, proposes a new type, high quality and sustainable programme for education and training in Safety Sciences for Medicines (S2M). The tailor-made training modules will encompass the safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on integrative, translational and 3Rs aspects of drug safety assessment. Individual safety professionals who wish to address specific knowledge gaps will be able to follow single modules. The modular set up also provides an excellent opportunity for following dedicated sub-sets of modules, to be accredited for Continuing Professional Development (CPD). Scientists successfully completing the full programme, including an integrative MSc-thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines (M4S2M). All training modules and procedures will be aligned with the Bologna process. Principle learning outcomes are novel competences in translational safety sciences, leading to safety scientists who are able to perform holistic and critical evaluations of the safety of drug candidates and new medicines by linking of animal and patient data.

Keywords: safescimet
European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,France,France,Belgium,Sweden,Germany,Germany,United Kingdom,Netherlands,United Kingdom,Denmark,Belgium,Spain,Denmark,Finland,France,United Kingdom,Netherlands,Italy
Call:  (IMI-JU-01-2008, 2008)
Start date: 2009-09-01
End date: 2016-06-30
Duration (months): 82.0
Total project cost (EUR): 8018904.0
EU funding (EUR): 3708225.0
Participants: 24
Project status: CLOSED

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with a proven record including the University of Bordeaux (Eu2P coordinator), the Autonomous University of Barcelona, the Erasmus University Medical Center, the University of Utrecht, the University of Hert[ordshire, the University of Verona, the Karolinska Institute and the European Medicines Agency. It will deliver programmes in harmacovigilance and Pharmacoepidemiology for continuing education diploma, Master’s degree as well as PhD and a short course orientated towards risk communication. Targeted audiences will be all those involved in the medicine evaluation processes including specialists from academia,industry and regulatory bodies as well as non-specialists (e.g. journalists, ethics committee members, patient organizations...). The Eu2P project is composed of one management work package (WP), one administrative WP and six programme topic WPs. This structure leaves open the addition of WPs by other partners. Modules will be developed in each programme topic WP to meet the needs of each type of course and target audience leading to WP cross-interaction. To facilitate access and flexibility (modular workload), the Eu2P programme will be based on English blended learning: a mix of face-to-face, e-Teaching and e-Learning courses. The first phase of the project (1 year) will establish the Eu2P programme and the e-Teaching and e-Learning centre. The second phase (4 years) will deliver, evaluate and promote the training programmes. Long-term viability of the programme will be assured by the learning experience and the resulting quality of trained persons, the demand for these and the financial balance.

Keywords: eu2p
New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours (PREDECT)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: France,Finland,Switzerland,Israel,Portugal,Netherlands,Netherlands,Estonia,Sweden,Germany,Germany,Germany,Belgium,United Kingdom,United States,Germany,Italy
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-02-01
End date: 2016-04-30
Duration (months): 63.0
Total project cost (EUR): 21020760.0
EU funding (EUR): 8756641.0
Participants: 21
Project status: CLOSED

Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel therapeutic targets. Known targets, in canonical pathways, will be interrogated for induction of phenotypic, proteomic and transcriptomic changes using inhibitors. A strategy of seeking a ‘dynamic reciprocity’ of concordance between the steady and perturbed states of in vitro complex cultures, tissue slices and in vivo tumour models will be pursued by systems biology analyses. Comparison with historic gene expression and genomic data from relevant clinical materials should permit the emergence of faithful models for target validation and beyond. PREDECT is coordinated by Servier and AstraZeneca, and the managing entity of IMI JU funding is the University of Helsinki. The team assembles world-class biologists, clinicians and computational scientists from 8 prestigious EU institutes, 3 SMEs and 8 EFPIA members to develop and critically assess models for target validation. The interaction between pharmaceutical and academic participants will be proactive, through postdoc co-supervision and work package co-piloting. We propose to develop and generate a repository of advanced complex models in 3 complementary areas: (i) in vitro 2D/3D organotypic (co-)cultures, stirred bioreactor aggregates and tissue slice systems; (ii) novel (orthotopic) grafts of human and mouse tumour samples; and (iii) genetically-engineered and mosaic mouse models. The deliverables of PREDECT are expected to shift paradigms in target validation, permitting greater predictivity of drug efficacy in patient cohorts.

Keywords: drug target validation,carcinoma,complex models,cell culture,tissue slice,gemm,systems biology